Beyhan Ataseven

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center "Surgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)".

Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center "Surgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)".

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 07, 2026

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Journal: Geburtshilfe und Frauenheilkunde

Published: February 03, 2026

ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.

ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 19, 2026

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Journal: NPJ breast cancer

Published: December 04, 2025

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Journal: Geburtshilfe und Frauenheilkunde

Published: December 19, 2024

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Journal: The New England journal of medicine

Published: December 12, 2024

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.

NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.

Journal: Gynecologic oncology

Published: November 14, 2024

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Journal: Gynecologic oncology

Published: September 11, 2024

2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both.

2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 29, 2024

Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.

Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.

Journal: Gynecologic oncology

Published: April 19, 2024

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 08, 2024

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer.

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: February 26, 2024

Showing 1-12 of 112

Last Updated: 09/26/2026